Patents Assigned to Shire BioChem Inc.
-
Patent number: 7528164Abstract: The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R1, R3-R5, A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: May 16, 2003Date of Patent: May 5, 2009Assignees: Cytovia, Inc., Shire BioChem, Inc.Inventors: Sui Xiong Cai, Songchun Jiang, William E. Kemnitzer, Hong Zhang, Giorgio Attardo, Real Denis
-
Patent number: 7501514Abstract: Single enantionmers of compounds of formula (B), in either the cis or trans configuration, wherein R1 and R2 are as defined herein, can be separated from enantiomeric mixtures thereof by reacting the compound with an acid to produce a conglomerate salt that has the following characteristics: the IR spectrum of the salt of the racemic compound, a 1:1 mixture of (?) and (+) crystals, is identical to that of the each of the single enantiomer, and the salt of the racemic compound has a melting point lower that that of either single enantiomer. The conglomerate salt is then separated by preferential crystallization.Type: GrantFiled: October 15, 2004Date of Patent: March 10, 2009Assignee: Shire Biochem, Inc.Inventors: Dragos Vizitiu, Ioana R. Simion, legal representative, Jean-Eric Lacoste, Dan Simion
-
Publication number: 20090017133Abstract: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of (a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or (b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and (c) compressing the resulting mixture into a tablet or filling up the resulting mixture in an appropriate container.Type: ApplicationFiled: September 24, 2008Publication date: January 15, 2009Applicant: Shire Biochem Inc.Inventors: Robert Paul Haslam, Laura Anna Trespidi, Josephine Christine Ferdinando
-
Patent number: 7476741Abstract: The present invention is directed to substituted 4H-chromenes, 2H-chromenes, chromans and analogs thereof, represented by the general Formula (I) wherein R5, A, B, X, Y, Z and dotted lines are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: May 16, 2003Date of Patent: January 13, 2009Assignees: Cytovia, Inc., Shire BioChem, Inc.Inventors: Sui Xiong Cai, Songchun Jiang, Giorgio Attardo, Réal Denis, Richard Storer, Rabindra Rej
-
Patent number: 7465465Abstract: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.Type: GrantFiled: August 26, 2004Date of Patent: December 16, 2008Assignee: Shire Biochem Inc.Inventors: Robert Paul Haslam, Laura Anna Trespidi, Josephine Christine Ferdinando
-
Patent number: 7442813Abstract: The present invention relates to a process conducted in a single reaction vessel for producing a dioxolane nucleoside analogue of formula I or a pharmaceutically acceptable salt thereof; the process comprising the steps of adding a Lewis acid, a silylating agent and a non-silylated purine or pyrimidine base or an analogue thereof to a dioxolane of formula II. The invention also provides a process for producing a dioxolane compound of formula III; by reacting a dioxolane compound of formula IV in a suitable solvent in the presence of DIB and I2, using a suitable source of energy.Type: GrantFiled: March 5, 2007Date of Patent: October 28, 2008Assignee: Shire Biochem Inc.Inventors: Gregory Bydlinski, Qing Yu, Alex Cimpoia
-
Patent number: 7230100Abstract: A process for producing predominantly cis nucleosides or nucleoside analogues and derivatives of formula (A): wherein R1 is a pyrimidine base or a pharmaceutically acceptable derivative thereof and Q is oxygen, carbon or sulphur, comprising a coupling step of the pyrimidine base with a molecule of formula (B) described herein in a suitable coupling solvent, in the presence of catalytic amounts of an element or combination of elements of groups IB or IIB of the periodic table, a tertiary amine and a Lewis acid to obtained an intermediate of formula (D) which is deprotected in the subsequent step to generate the product of formula (A).Type: GrantFiled: April 7, 2006Date of Patent: June 12, 2007Assignee: Shire BioChem., Inc.Inventor: Qing Yu
-
Patent number: 7122693Abstract: The acetaldehyde compounds, 2-thiobenzoylacetaldehyde diethylacetal, 2-benzoyloxyacetaldehyde bis(2-methoxyethyl)acetal, 2-hydroxyacetaldehyde bis( 2-methoxyethyl)acetal, 2-thiobenzoylacetaldehyde bis(2-methoxy-ethyl)acetal, and 2-thioacetaldehyde bis(2-methoxyethyl)acetal, are useful as intermediates in the synthesis of substituted 1,3-oxathiolanes and substituted 1,3-dioxolanes.Type: GrantFiled: July 9, 2004Date of Patent: October 17, 2006Assignee: Shire BioChem Inc.Inventors: Pierette Belleau, executrix of estate, Dilip M. Dixit, Nghe Nguyen-Ba, Bernard Belleau, deceased
-
Patent number: 7109334Abstract: A process for producing predominantly cis nucleosides or nucleoside analogues and derivatives of formula (A): wherein R1 is a pyrimidine base or a pharmaceutically acceptable derivative thereof and Q is oxygen, carbon or sulphur, comprising a coupling step of the pyrimidine base with a molecule of formula (B) described herein in a suitable coupling solvent, in the presence of catalytic amounts of an element or combination of elements of groups IB or IIB of the periodic table, a tertiary amine and a Lewis acid to obtained an intermediate of formula (D) which is deprotected in the subsequent step to generate the product of formula (A).Type: GrantFiled: June 14, 2002Date of Patent: September 19, 2006Assignee: Shire BioChem, Inc.Inventor: Qing Yu
-
Patent number: 7015328Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: May 16, 2002Date of Patent: March 21, 2006Assignees: Cytovia, Inc., Shire BioChem Inc.Inventors: Sui Xiong Cai, Hong Zhang, William E. Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
-
Patent number: 6964968Abstract: Viral infections selected from the group consisting of herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus can be treated by administering to the host a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; wherein Y, Ra, and R1 are as defined herein. The compounds and salts can also be used to inhibit viral replication of these viruses in cells.Type: GrantFiled: March 31, 2003Date of Patent: November 15, 2005Assignee: Shire Biochem, Inc.Inventors: Francis J. Giles, Jean Bédard, Robert F. Rando
-
Patent number: 6960594Abstract: A novel compound which inhibits certain integrins, particularly ?v integrins. Additionally, the novel compound may be used in a method of treating tumors or cancer which comprises administering a pharmaceutically effective amount of the compound to a patient. Additionally, the novel compound may be used in a method of inhibiting angiogensis. Finally, a method of producing the novel compound is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: November 1, 2005Assignee: Shire BioChem Inc.Inventors: Denis Labrecque, Serge Lamothe, Marc Courchesne, Laval Chan, Giorgio Attardo, Karen Meerovitch
-
Patent number: 6900325Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: May 16, 2002Date of Patent: May 31, 2005Assignees: Cytovia, Inc., Shire BioChem Inc.Inventors: Sui Xiong Cai, Hong Zhang, William E. Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
-
Patent number: 6887879Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of viral infections comprising a at least one antiviral active compound of formula (1): and at least one further therapeutic agent chosen from nucleoside analogues; NNRTIs; and protease inhibitors.Type: GrantFiled: May 16, 2002Date of Patent: May 3, 2005Assignee: Shire BioChem Inc.Inventors: Robert F. Rando, Zhengxian Gu
-
Publication number: 20050090526Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: ApplicationFiled: November 16, 2004Publication date: April 28, 2005Applicants: Cytovia, Inc., Shire BioChem, Inc.Inventors: Sui Cai, Hong Zhang, William Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
-
Publication number: 20050085638Abstract: The present invention relates to a process conducted in a single reaction vessel for producing a dioxolane nucleoside analogue of formula I or a pharmaceutically acceptable salt thereof; the process comprising the steps of adding a Lewis acid, a silylating agent and a non-silylated purine or pyrimidine base or an analogue thereof to a dioxolane of formula II. The invention also provides a process for producing a dioxolane compound of formula III; by reacting a dioxolane compound of formula IV in a suitable solvent in the presence of DIB and I2, using a suitable source of energy.Type: ApplicationFiled: January 23, 2003Publication date: April 21, 2005Applicant: SHIRE BIOCHEM INCInventors: Gregory Bydlinski, Qing Yu, Alex Cimpoia
-
Patent number: 6831174Abstract: Disclosed are processes for preparing compounds of the formula (I) and pharmaceutically acceptable salts or esters thereof: wherein R2 is a purine or pyrimidine base or an analogue or derivative thereof; and Z is S, S═O or SO2. The invention also relates to intermediates of use in the preparation of these compounds.Type: GrantFiled: January 16, 2001Date of Patent: December 14, 2004Assignee: Shire BioChem Inc.Inventors: Bernard Belleau, Tarek Mansour, Allan Tse, Colleen A. Evans, Haolun Jin, Boulos Zacharie, Nghe Nguyen-Ba
-
Patent number: 6800639Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.Type: GrantFiled: March 25, 2002Date of Patent: October 5, 2004Assignee: Shire BioChem Inc.Inventors: Francis Giles, Hagpop Kantarjian, Jacques Jolivet
-
Publication number: 20040132652Abstract: Pharmaceutical compositions comprising a liposome associated to N. meningitidis polypeptides fragments or analogs thereof or corresponding DNA fragments, can be used to prevent, diagnose and/or treat neisserial infections.Type: ApplicationFiled: August 28, 2003Publication date: July 8, 2004Applicant: Shire BioChem Inc.Inventors: Denis Martin, Stephane Rioux
-
Patent number: RE39155Abstract: Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.Type: GrantFiled: January 3, 1992Date of Patent: July 4, 2006Assignee: Shire BioChem Inc.Inventors: Pierrette Belleau, Nghe Nguyen-Ba, Bernard Belleau